# CardioFocus

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cardiofocus

- Industry: Medical Devices & Equipment
- Headquarters: Marlborough, US
- Website: www.cardiofocus.com
- Total disclosed funding: $67M
- Latest round: Series D (Dec 22, 2014)
- Investors on record: 11

## About

CardioFocus, Inc. is a US-based medical technology company that specializes in developing advanced solutions for treating atrial fibrillation, enhancing precision and efficiency in electrophysiology procedures.Founded in 1990 and headquartered in Marlborough, US, CardioFocus, Inc. focuses on innovative medical technologies for atrial fibrillation treatment. The company has completed 18 total deals, with its most recent funding round being Series E in February 2023, raising USD 8.00 mn, amounting to a total capital raised of USD 8.00 mn. Burke Barrett and Stephan Ogilvie currently lead the company as CEOs.CardioFocus specializes in advanced technologies for treating atrial fibrillation (AF). Its flagship products include the HeartLight X3 system and the Centauri PFA system, which utilize innovative laser technology and customized monopolar biphasic waveform designs for enhanced precision in ablation procedures. These products serve hospitals and electrophysiology labs across North America and Europe, particularly for healthcare professionals addressing complex cardiac arrhythmias.The revenue model of CardioFocus is based on direct sales of its medical devices to healthcare institutions, including hospitals and electrophysiology practices. The company’s offerings, such as the HeartLight X3 and Centauri PFA systems, are pivotal for minimally invasive ablation procedures for atrial fibrillation. The pricing structures reflect the advanced technology of these products and usually include ongoing support and training for medical staff, establishing long-term partnerships with healthcare providers to ensure they are equipped with the latest innovations in cardiac care.In February 2023, CardioFocus, Inc. secured additional funding as part of a larger USD 27.16 million equity and venture debt round. This funding will be instrumental in driving the development of new products and supporting market expansion efforts. The company is targeting new geographic regions for its advanced technologies, although specific regions have not been disclosed. Strategic initiatives will focus on enhancing product offerings and improving service capabilities in the electrophysiology space.

## Funding rounds

- Series D, Dec 22, 2014, $32M — Aurora Funds, Oxford Bioscience Partners, Fletcher Spaght Ventures, Accuitive Medical Ventures, SV Health Investors, KBL Healthcare Ventures, H.I.G. BioHealth Partners, Kestrel Ventures, MassVentures, First Alliance & Capital Invest, Manatuck Hill Partners
- Series C, Feb 10, 2011, $14M — Aurora Funds, Oxford Bioscience Partners, Fletcher Spaght Ventures, Accuitive Medical Ventures, SV Health Investors, KBL Healthcare Ventures, Kestrel Ventures
- Series C, May 22, 2008, $9.1M — Aurora Funds, SV Health Investors, Kestrel Ventures
- Series C, Apr 24, 2006, $13M — Aurora Funds, Oxford Bioscience Partners, Accuitive Medical Ventures, SV Health Investors, KBL Healthcare Ventures, H.I.G. BioHealth Partners, Kestrel Ventures
- Series A, Jun 1, 1997 — Kestrel Ventures

## Investors

- Kestrel Ventures (https://capitalatlas.ai/funds/kestrel-ventures) — Series A, Series C, Series D
- Aurora Funds (https://capitalatlas.ai/funds/aurora-funds) — Series C, Series D
- Oxford Bioscience Partners (https://capitalatlas.ai/funds/oxford-bioscience-partners) — Series C, Series D
- Accuitive Medical Ventures (https://capitalatlas.ai/funds/accuitive-medical-ventures) — Series C, Series D
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series C, Series D
- KBL Healthcare Ventures (https://capitalatlas.ai/funds/kbl-healthcare-ventures) — Series C, Series D
- H.I.G. BioHealth Partners (https://capitalatlas.ai/funds/h-i-g-biohealth-partners) — Series C, Series D
- Fletcher Spaght Ventures (https://capitalatlas.ai/funds/fletcher-spaght-ventures) — Series C, Series D
- MassVentures (https://capitalatlas.ai/funds/massventures) — Series D
- First Alliance & Capital Invest — Series D
- Manatuck Hill Partners — Series D